Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enli Liu

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2021
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30<sup>+</sup> MalignanciesLucila N Kerbauy, Nancy D Marin, Mecit Kaplan, et al.
Cancer Discovery|June 20, 2024
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling AxisSunil Acharya, Rafet Basar, May Daher, et al.
Science Translational Medicine|September 11, 2024
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AMLBijender Kumar, Anand Singh, Rafet Basar, et al.
The Journal of Clinical Investigation|June 17, 2021
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cellsHila Shaim, Mayra Shanley, Rafet Basar, et al.
Blood|September 9, 2020
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cellsMay Daher, Rafet Basar, Elif Gokdemir, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2021
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30<sup>+</sup> MalignanciesLucila N Kerbauy, Nancy D Marin, Mecit Kaplan, et al.
Cancer Discovery|June 20, 2024
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling AxisSunil Acharya, Rafet Basar, May Daher, et al.
Science Translational Medicine|September 11, 2024
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AMLBijender Kumar, Anand Singh, Rafet Basar, et al.
The Journal of Clinical Investigation|June 17, 2021
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cellsHila Shaim, Mayra Shanley, Rafet Basar, et al.
Blood|September 9, 2020
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cellsMay Daher, Rafet Basar, Elif Gokdemir, et al.
Pageof 7